

SHEET 1 OF 7

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066817-0024	SERIAL NO. 10/806,771
	APPLICANT	
	FILING DATE March 22, 2004	GROUP 1654

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	5,268,164	12-07-1993	Kozarich et al.	
	2.	5,338,686	08-16-1994	Hellerstein	
	3.	5,506,206	04-09-1996	Kozarich et al.	
	4.	5,550,138	08-27-1996	Sohda et al.	
	5.	5,686,416	11-11-1997	Kozarich et al.	
	6.	5,691,368	11-25-1997	Peet et al.	
	7.	5,698,519	12-16-1997	Katsunuma et al.	
	8.	5,776,718	07-07-1998	Palmer et al.	
	9.	5,883,121	03-16-1999	Yamashita et al.	
	10.	5,925,633	07-20-1999	Singh et al.	
	11.	5,925,772	07-20-1999	Zimmerman et al.	
	12.	5,955,491	09-21-1999	Sohda et al.	
	13.	6,143,931	11-07-2000	Baldino et al.	
	14.	6,329,163	12-11-2001	Anderson et al.	
	15.	6,353,017	03-05-2002	Altmann et al.	
	16.	6,458,760	10-01-2002	Seyfried et al.	
	17.	6,468,977	10-22-2002	Karimian et al.	
	18.	60/456,869	03-21-2003	Hook	

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Code ³ -Number 4-Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation	
		WO 94/104172 **	03-03-1994			Yes	No
		EP 0 603 873 **					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

EXAMINER SDO 79588-1.066817.0024	DATE CONSIDERED
--	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

**** This reference is not attached. Will provide under separate cover.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TH/

SHEET 2 OF 7

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066817-0024	SERIAL NO. 10/806,771
	APPLICANT	
	FILING DATE March 22, 2004	GROUP 1654

19.	Alzheimer's Disease Collaborative Group, "The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families." <u>Nature Genet.</u> 11:219-222 (1995). **	
20.	Asanuma et al., "Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes." <u>Kidney Int.</u> 62(3):822-831 (2002). **	
21.	Azaryan and Hook, "Distinct properties of prohormone thiol protease (PTP) compared to cathepsins B, L, and H: evidence for PTP as a novel cysteine protease," <u>Arch. Biochem. Biophys.</u> 314:171-177 (1994). **	
22.	Azaryan et al., "Purification and characteristics of the candidate prohormone processing proteases PC2 and PC1/8 from bovine adrenal medulla chromaffin granules," <u>J. Biol. Chem.</u> 270:8201-8208 (1995). **	
23.	Barrett et al., <u>Handbook of Proteolytic Enzymes</u>, 600-617, Academic Press, San Diego (1998). **	
24.	Dogyo et al., "Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs." <u>Chem. Biol.</u> 1:27-38 (2000). **	
25.	Borchelt et al., "Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo," <u>Neuron</u> 17:1005-1013 (1996). **	
26.	Cathers, et al., "pH Dependence of inhibitors targeting the occluding loop of cathepsin B," <u>Bioorg. Chem.</u> 30(4):264-275 (2002). **	
27.	Chie et al., "Probing single secretory vesicles with capillary electrophoresis," <u>Science</u> 279:1130-1133 (1998). **	
28.	Chowdhury et al., "Design of noncovalent inhibitors of human cathepsin L. From the 96-residue proregion to optimized tripeptides," <u>J. Med. Chem.</u> 45(24):5321-5329 (2002).	
29.	Coligan et al., Eds., <i>Current Protocols in Protein Science</i> , Vol. 1 and 2, Ch. 4, pp. 4.0.1-4.3.21, John Wiley and Sons. **	
30.	Coligan et al., Eds., <i>Current Protocols in Protein Science</i> , Vol. 1 and 2, Ch. 4, pp. 4.5.1-4.5.38, John Wiley and Sons. **	
31.	Dixon et al., Eds., <i>Enzymes</i> , pp. 11-12, Academic Press (1970). **	
32.	Fricker et al., "Cloning and sequence analysis of cDNA for bovine carboxypeptidase E," <u>Nature</u> 323:461-464 (1986). **	
33.	Fujishima et al., "The crystal structure of human cathepsin L complexed with E-64," <u>FEBS Lett.</u> 407:47-50 (1997). **	
34.	Glenner et al., "Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein," <u>Biochem. Biophys. Res. Commun.</u> 120:885-890 (1984). **	

EXAMINER SDO 79588-1.066817.0024	DATE CONSIDERED
---	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference is not attached. Will provide under separate cover.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TH/

SHEET 3 OF 7

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066817-0024	SERIAL NO. 10/806,771
	APPLICANT	
	FILING DATE March 22, 2004	GROUP 1654

35.	Gour-Salin et al., "Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein," <u>J. Med. Chem.</u> 36:720-725 (1993). **
36.	Greenbaum et al., "A specificity switch in selected cre recombinase variants is mediated by macromolecular plasticity and water," <u>Chem. Biol.</u> 10:1085-1094 (2002). **
37.	Greenbaum et al., "Chemical approaches for functionally probing the proteome," <u>Mol. Cell. Proteomics</u> 1:60-68 (2002). **
38.	Greenbaum et al., "Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools," <u>Chem. Biol.</u> 7:569-581 (2000). **
39.	Greenspan et al., "Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design," <u>J. Med. Chem.</u> 44:4524-4534 (2002). **
40.	Guncar et al., "Crystal structure of MHC class II-associated p41 li fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and G," <u>EMBO J.</u> 18(4):793-803 (1999). **
41.	Guo et al., "Inhibition of MEPE cleavage by Phex," <u>Biochem. Biophys. Res. Commun.</u> 297(1):38-45 (2002). **
42.	Hines et al., "The expression and processing of human beta-amyloid peptide precursors in <i>Saccharomyces cerevisiae</i> : evidence for a novel endopeptidase in the yeast secretory system," <u>Cell. Molec. Biol. Res.</u> 40:273-284 (1994). **
43.	Hook and Eiden, "Two peptidases that convert 125I-Lys-Arg-(Met)enkephalin and 125I-(Met)enkephalin-Arg6, respectively, to 125I-(Met)enkephalin in bovine adrenal medullary chromaffin granules," <u>FEBS Lett.</u> 172:212-218 (1984). **
44.	Hook et al., "A carboxypeptidase processing enzyme for enkephalin precursors." <u>Nature</u> 295:341-342 (1982). **
45.	Hook et al., "Evidence for functional localization of the proenkephalin-processing enzyme, prohormone thiol protease, to secretory vesicles of chromaffin cells," <u>Endocrinol.</u> 140:3744-3754 (1999). **
46.	Hook et al., "Proteases and the emerging role of protease inhibitors in prohormone processing," <u>EASEB J.</u> 8:1269-1278 (1994). **
47.	Hook et al., "Selective regulation of carboxypeptidase peptide hormone-processing enzyme during enkephalin biosynthesis in cultured bovine adrenomedullary chromaffin cells," <u>J. Biol. Chem.</u> 260:5991-5997 (1985). **
48.	Hook et al., "Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta secretase activity in chromaffin vesicles," <u>J. Neurochem.</u> 81:237-256 (2002). **
49.	Hsiao, "From prion diseases to Alzheimer's disease," <u>J Neural Transm Suppl.</u> , 49:135-144 (1997). **

EXAMINER SDO 79588-1.066817.0024	DATE CONSIDERED
-------------------------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference is not attached. Will provide under separate cover.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TH/

SHEET 4 OF 7

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066817-0024	SERIAL NO. 10/806,771
	APPLICANT	
	FILING DATE March 22, 2004	GROUP 1654

50.	Irving et al., "Inhibitory activity of a heterochromatin-associated serpin (MENT) against papain-like cysteine proteinases affects chromatin structure and blocks cell proliferation," <u>J. Biol. Chem.</u> 277(15):13192-13201 (2002). **
51.	Jane et al., "Selective inhibition of cathepsin B with cell-permeable CA074Me negatively affects L6 rat myoblast differentiation," <u>Biochem. Cell Biol.</u> 80(4):457-465 (2002).
52.	Johnson-Wood et al., "Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease," <u>Proc. Natl. Acad. Sci. USA</u> , 94:1550-1555 (1997). **
53.	Kang et al., "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor," <u>Nature</u> 325:733-736 (1987). **
54.	Katunuma et al., "Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo," <u>FEBS Lett.</u> 458:6-10 (1999). **
55.	Katunuma et al., "Structure-based design of specific cathepsin inhibitors and their application to protection of bone metastases of cancer cells," <u>Arch. Biochem. Biophys.</u> 397(2):305-311 (2002). **
56.	Katunuma et al., "Structure-based development of cathepsin L inhibitors and therapeutic applications for prevention of cancer metastasis and cancer-induced osteoporosis," <u>Advan. Enzyme Regul.</u> 42:159-172 (2002). **
57.	Kirschke, "Cathepsin B, Cathepsin H and Cathepsin L," in <u>Methods of Enzymology</u> , 1981:80 Pt. C pp. 535-561 and Swiss-Prot database). **
58.	Kitaguchi et al., "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor," <u>Nature</u> 331:530-532 (1988). **
59.	Knops et al., "Purification and characterization of a novel thiol protease involved in processing the enkephalin precursor," <u>J. Biol. Chem.</u> 266:7285-7290 (1991). **
60.	Koo," Phorbol esters affect multiple steps in beta-amyloid precursor protein trafficking and amyloid beta-protein production," <u>Molec. Medicine</u> , 3:204-211 (1997). **
61.	Krieger and Hook, "Purification and characterization of a novel thiol protease involved in processing the enkephalin precursor," <u>J. Biol. Chem.</u> 266:8376-8383 (1991) **
62.	Krieger et al., "Purification and characterization of a cathepsin D protease from bovine chromaffin granules," <u>Biochemistry</u> 31:4223-4231 (1992). **
63.	Krieger et al., "Prohormone thiol protease and enkephalin precursor processing: cleavage at dibasic and monobasic sites," <u>J. Neurochem.</u> 59:26-31 (1992). **
64.	Kurata et al., "Bombyx cysteine proteinase inhibitor (BCPI) homologous to propeptide regions of cysteine proteinases is a strong, selective inhibitor of cathepsin L-like cysteine proteinases," <u>J. Biochem. (Tokyo)</u> 130(6):857-863 (2001). **
65.	Kusunoki et al., "Cathepsin L activity and its inhibitor in human otitis media," <u>J. Otolaryngol.</u> 30(3):157-161 (2001).

EXAMINER SDO 79588-1.066817.0024	DATE CONSIDERED
---	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference is not attached. Will provide under separate cover.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TH/

SHEET 5 OF 7

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066817-0024	SERIAL NO. 10/806,771
	APPLICANT	
	FILING DATE March 22, 2004	GROUP 1654

66.	Laemmli, "Cleavage of structural proteins during the assembly of the head of bacteriophage T4," <u>Nature</u> 227:259, 680-685 (1970). **	
67.	LeBanc et al., "Protein Kinase C Activation Increases Release of Secreted Amyloid Precursor Protein without Decreasing A β Production in Human Primary Neuron Cultures," <u>J. Neurosci.</u> 18:2907-2913 (1998). **	
68.	Loh et al., "Measurement of delta pH and membrane potential in secretory vesicles isolated from bovine pituitary intermediate lobe," <u>J. Biol. Chem.</u> 250:8238-8245 (1984). **	
69.	Mann et al., "Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene," <u>Am. J. Path.</u> 148:1257-1266 (1996). **	
70.	Manser et al., "Human carboxypeptidase E. Isolation and characterization of the cDNA, sequence conservation, expression and processing in vitro," <u>Biochem. J.</u> 267:517-525 (1990). **	
71.	Masters et al., "Amyloid plaque core protein in Alzheimer disease and Down syndrome," <u>Proc. Natl. Acad. Sci. USA</u> 82:4245-4249 (1985). **	
72.	McDonald and Barrett, Eds., <i>Mammalian Proteases, a Glossary and Bibliography</i> , Academic Press, p. 23-99 (1986). **	
73.	Montaser et al., "A-074, but not its methyl ester CA-074Me, is a selective inhibitor of cathepsin B within living cells," <u>Biol. Chem.</u> 383(7-8):1305-1308 (2002). **	
74.	Niestroj et al., "Human carboxypeptidase E. Isolation and characterization of the cDNA, sequence conservation, expression and processing in vitro," <u>Biol. Chem.</u> 383:1205-1214 (2002). **	
75.	Niestroj et al., "Inhibition of mammalian legumain by Michael acceptors and AzaAsn-halomethylketones," <u>Biol. Chem.</u> 383:1205-1214 (2002). **	
76.	Pagano et al., "Inhibition of cathepsin L and B by haptoglobin, the haptoglobin-hemoglobin complex, and asialohaptoglobin. "In vitro" studies in the rat," <u>Can. J. Biochem.</u> 60:631-637 (1982). **	
77.	Pharma Japan, September 1995, 1468, 23. **	
78.	Pollard et al., "Internal pH and state of ATP in adrenergic chromaffin granules determined by ³¹ P nuclear magnetic resonance spectroscopy," <u>J. Biol. Chem.</u> 254:1170-1177 (1979). **	
79.	Ponte et al., "A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors," <u>Nature</u> 331:525-527 (1988). **	
80.	Potempa et al., "Host and Porphyromonas gingivalis proteinases in periodontitis: A biochemical model of infection and tissue destruction," <u>Perspectives in Drug Discovery and Design</u> , 2:445-458 (1994). **	

EXAMINER SDO 79588-1.066817.0024	DATE CONSIDERED
---	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference is not attached. Will provide under separate cover.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TH/

SHEET 6 OF 7

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066817-0024	SERIAL NO. 10/806,771
	APPLICANT	
	FILING DATE March 22, 2004	GROUP 1654

81.	Rigden et al., "Sequence conservation in the chagasin family suggests a common trend in cysteine proteinase binding by unrelated protein inhibitors," <u>Protein Sci.</u> 11(8):1971-1977 (2002). **
82.	Russell, "The isolation of purified neurosecretory vesicles from bovine neurohypophysis using isoosmolar density gradients," <u>Anal. Biochem.</u> 113:229-238 (1981). **
83.	Rydzewski et al., "Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity," <u>Bioorganic & Medicinal Chem.</u> 10:3277-3284 (2002). **
84.	Saegusa et al., "Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity," <u>J. Clin. Invest.</u> 110(3):361-369 (2002). **
85.	Schaschke et al., "Epoxysuccinyl peptide-derived cathepsin B inhibitors: modulating membrane permeability by conjugation with the C-terminal heptapeptide segment of penetratin," <u>Biol. Chem.</u> 383:849-852 (2002). **
86.	Selkoe et al., "Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease," <u>J. Neurochem.</u> 46:1820-1834 (1986). **
87.	Selkoe, "Amyloid beta-protein and the genetics of Alzheimer's disease," <u>J. Biol. Chem.</u> 271:18295-18298 (1996). **
88.	Sever, et al., "Effect of cysteine proteinase inhibitors on murine B16 melanoma cell invasion in vitro," <u>Biol. Chem.</u> 383(5):839-842 (2002). **
89.	Sices and Kristie, "A genetic screen for the isolation and characterization of site-specific proteases," <u>Proc. Natl. Acad. Sci. USA</u> 95:2828-2833 (1988). **
90.	St. George-Hyslop et al., "An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants," <u>Science</u> 264:1336-1340 (1994). **
91.	Tanzi et al., "Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus," <u>Science</u> 235:880-884 (1987).
92.	Tanzi et al., "Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease," <u>Nature</u> 331:528-530 (1988). **
93.	Tezapsidis et al., "Release of nontransmembrane full-length Alzheimer's amyloid precursor protein from the luminal surface of chromaffin granule membranes," <u>Biochem.</u> 37:1274-1282 (1998). **
94.	Tezapsidis et al., "Stimulation of "prohormone thiol protease" (PTP) and [Met]enkephalin by forskolin. Blockade of elevated [Met]enkephalin by a cysteine protease inhibitor of PTP," <u>J. Biol. Chem.</u> 270:13285-13290 (1995). **
95.	Toomin et al., "Thiol and aspartyl proteolytic activities in secretory vesicles of bovine pituitary," <u>Biochem. Biophys. Res. Commun.</u> 183:449-455 (1992). **

EXAMINER SDO 79588-1.066817.0024	DATE CONSIDERED
---	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference is not attached. Will provide under separate cover.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TH/

SHEET 7 OF 7

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066817-0024	SERIAL NO. 10/806,771
	APPLICANT	
	FILING DATE March 22, 2004	GROUP 1654

96.	Van Ackjer et al., "Cathepsin B inhibition prevents trypsinogen activation and reduces pancreatitis severity," <u>Am. J. Physiol. Gastrointest. Liver Physiol.</u> 283:G794-800 (2002). **	
97.	Vassilacopoulou et al., "Full-length and truncated Alzheimer amyloid precursors in chromaffin granules: solubilization of membrane amyloid precursor is mediated by an enzymatic mechanism," <u>J. Neurochem.</u> 64:2140-2146 (1995). **	
98.	Voet et al., <u>Biochemistry</u> , pp. 284-288, John Wiley & Sons, (1990). **	
99.	Voet et al., <u>Biochemistry</u> , pp.382-388, John Wiley & Sons, and 750-755 (1990). **	
100.	Voet et al., <u>Biochemistry</u> , pp. 35-39, John Wiley and Sons (1990). **	
101.	Wang et al., "Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors," <u>Biochemistry</u> 41(28):8849-8859 (2002). **	
102.	Wasco et al., "Familial Alzheimer's chromosome 14 mutations," <u>Nature Med.</u> 1(9):848 (1995). **	
103.	Wieczerezak et al., "Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases," <u>J. Med. Chem.</u> 45(19):4202-4211 (2002). **	
104.	Yamamoto et al., "Crystallization and preliminary X-ray study of the cathepsin B complexed with CA074, a selective inhibitor," <u>J. Mol. Biol.</u> 227:942-944 (1992). **	
105.	Yamamoto et al., "Novel cysteine proteinase inhibitors homologous to the proregions of cysteine proteinases," <u>Curr. Protein Rept. Sci.</u> 3(2):231-238 (2002). **	
106.	Yamamoto et al., "Structural basis for development of cathepsin B-specific noncovalent-type inhibitor: crystal structure of cathepsin B-E64c complex," <u>Biochim Biophys Acta</u> 1597(2):244-251 (2002). **	
107.	Yamamoto et al., "Substrate specificity of bovine cathepsin B and its inhibition by CA074, based on crystal structure refinement of the complex," <u>J. Biochem. (Tokyo)</u> 127(4):635-643 (2000). **	
108.	Yasothornsrikul et al., "Arginine and lysine aminopeptidase activities in chromaffin granules of bovine adrenal medulla: relevance to prohormone processing," <u>J. Neurochem.</u> 70:153-163 (1998). **	
109.	Yasothornsrikul et al., "Evidence for the proenkephalin processing enzyme prohormone thiol protease (PTP) as a multicatalytic cysteine protease complex: activation by glutathione localized to secretory vesicles," <u>Biochemistry</u> 38:7421-7430 (1999). **	

EXAMINER SDO 79588-1.066817.0024 /Thomas Heard/	DATE CONSIDERED 03/17/2008
---	--------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference is not attached. Will provide under separate cover.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TH/